The global NT growth factor receptor market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, new product launches, FDA approval, research, and development of new drugs to stay competitive in the market. For instance, in May 2021, FDA grants approval to amivantamab-vmjw, which is a bi-specific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptors.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/nt-growth-factor-receptor-market
Moreover, in May 2020, FDA approved selpercatinib, to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer. in May 2020, FDA also approved Pemazyre as the drug to treat adults with locally advanced, previously treated, advanced cholangiocarcinoma with tumors containing a fusion or other rearrangement of the fibroblast growth factor receptor 2 gene. In November 2018, FDA approved larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2022
- Forecast period- 2022-2028
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape – AstraZeneca, Daiichi Sankyo Co. Ltd., HANDOK Inc., Ignyta Inc., Loxo Oncology, and others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global NT Growth Factor Receptor Market Report Segment
By Type
- AZD-7451
- Larotrectinib
- DS-6051
- LM-22B10
- Others
By Application
- Breast cancer
- Brain cancer
- Solid tumor
- Colon cancer
- Fibrosarcoma
- Others
A full report of NT Growth Factor Receptor Market is available at: https://www.omrglobal.com/industry-reports/nt-growth-factor-receptor-market
NT Growth Factor Receptor Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca
- Daiichi Sankyo Co. Ltd.
- HANDOK Inc.
- Ignyta Inc.
- Loxo Oncology
- NETRIS Pharma
- Plexxikon
